Cognito to Present New Spectris™ Data for Alzheimer's at CTAD 2024

Cognito Therapeutics, a neurotechnology firm focused on developing therapies for central nervous system (CNS) disorders, has announced its participation in the upcoming 17th Clinical Trials on Alzheimer's Disease (CTAD) conference. The event will be held in Madrid, Spain, and online from October 29 to November 1, 2024. Cognito Therapeutics will present several posters detailing their innovative therapy, Spectris™, aimed at treating Alzheimer's Disease.

Christian Howell, CEO of Cognito Therapeutics, expressed enthusiasm about presenting new clinical data at CTAD. He highlighted the potential of Spectris™ to maintain brain function and structure in Alzheimer's patients. Howell also emphasized the company's commitment to advancing their novel, non-invasive therapy, particularly through the HOPE trial's diverse recruitment strategies that better represent the actual Alzheimer’s population.

Ralph Kern, M.D., MHSc, Chief Medical Officer at Cognito Therapeutics, added that Spectris™ has shown encouraging results by using non-invasive auditory and visual neuromodulation. The data indicate significant preservation of daily function and brain structure. Kern noted that the HOPE study aims to include a diverse group of participants, mirroring the real-world Alzheimer’s disease population. Kern reiterated the excitement about sharing this new data at the CTAD conference.

The details of the poster presentations are as follows:

- **Title**: "SPECTRIS™ Treatment Reduced Alzheimer’s Disease Dependence Score in OVERTURE I/II Phase 2 Study"
- **Format**: Poster 025
- **Presenter**: Marwan Sabbagh, MD, Barrow Neurological Institute
- **Session**: Poster Session 1
- **Date/Time**: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm

- **Title**: "SPECTRIS™ OVERTURE I responder analysis demonstrates consistent preservation of function and brain structure"
- **Format**: Poster 026
- **Presenter**: Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics
- **Session**: Poster Session 1
- **Date/Time**: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm

- **Title**: "Clinical Trial Enrichment Strategy for Participant Selection in the Phase 3 HOPE study of Alzheimer’s disease: Progress towards personalized medicine"
- **Format**: Poster LP005
- **Presenter**: Lily Lee, Ph.D., Vice President and Head of Medical Affairs, Cognito Therapeutics
- **Session**: Poster Session 1
- **Date/Time**: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm

- **Title**: "Diversity amongst the Phase 3 HOPE study participants is reflective of the real-world Alzheimer’s Disease (AD) population"
- **Format**: Poster LP099
- **Presenter**: Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics
- **Session**: Poster Session 3
- **Date/Time**: Fri Nov 1 at 7:15 am - 5 pm

- **Title**: "Comparison of visually evoked steady-state oscillations between two Spectris™ eyesets"
- **Format**: Poster LP028
- **Presenter**: Mihaly Hajos, Ph.D., Chief Science Officer, Cognito Therapeutics
- **Session**: Poster Session 1
- **Date/Time**: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm

- **Title**: "Effects of sensory-evoked gamma oscillation on neurophysiological signals of visual and cognitive processing in Alzheimer’s disease"
- **Format**: Poster LP016
- **Presenter**: Mihaly Hajos, Ph.D., Chief Science Officer, Cognito Therapeutics
- **Session**: Poster Session 1
- **Date/Time**: Tue Oct 29 at 3:00 pm - Wed Oct 30 at 5 pm

Cognito Therapeutics is at the forefront of developing groundbreaking neurotechnological treatments for neurodegenerative diseases. Their primary product, Spectris™, employs non-invasive auditory and visual neuromodulation to boost gamma frequency brain activity. This method aims to decelerate brain atrophy and alleviate functional decline in Alzheimer’s patients. Based in Cambridge, MA, Cognito Therapeutics is dedicated to creating transformative, technology-driven solutions to meet the unmet needs in CNS disease treatment.